Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients

被引:2
|
作者
Gualano, Bruno [1 ,2 ]
Saad, Carla G. S. [3 ]
Sieczkowska, Sofia M. [1 ]
Lemes, Italo Ribeiro [1 ]
da Silva, Rafael Pires [1 ]
Pinto, Ana J. [1 ,4 ]
Mazzolani, Bruna C. [1 ]
Smaira, Fabiana, I [1 ]
Gil, Saulo [1 ]
Oliveira-Junior, Gersiel [1 ]
Aikawa, Nadia E. [3 ]
Medeiros-Ribeiro, Ana C. [3 ]
Silva, Clovis A. [3 ,5 ]
Yuki, Emily F. N. [3 ]
Pasoto, Sandra G. [3 ]
Pereira, Rosa Maria R. [3 ]
Shinjo, Samuel K. [3 ]
Andrade, Danieli C. O. [3 ]
Sampaio-Barros, Percival D. [3 ]
Roschel, Hamilton [1 ]
Bonfa, Eloisa [3 ]
机构
[1] Univ Sao Paulo, Fac Med FMUSP, Sch Phys Educ & Sport, Div Rheumatol,Appl Physiol & Nutr Res Grp, Sao Paulo, Brazil
[2] Univ Sao Paulo, Food Res Ctr, Sao Paulo, Brazil
[3] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Div Rheumatol, Sao Paulo, Brazil
[4] Univ Colorado, Sch Med, Metab & Diabet & Anschutz Hlth & Wellness Ctr, Div Endocrinol, Anschutz Med Campus, Aurora, CO USA
[5] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Crianca & Adolescente,Pediat Rheumatol Unit, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
COVID-19; immunosuppression; physical activity; resistance exercise; Sinovac-CoronaVac; ECCENTRIC EXERCISE; PHYSICAL-ACTIVITY; RESPONSES; EFFICACY; ANTIBODY; ADJUVANT;
D O I
10.1152/japplphysiol.00015.2022
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
This randomized controlled study aimed to investigate whether a single bout of exercise before the homologous booster dose of a SARS-CoV-2 inactivated vaccine could enhance immunogenicity in patients with spondyloarthritis. We selected 60 consecutive patients with spondyloarthritis (SpA). Patients assigned to the intervention group performed an exercise bout comprising three exercises. Then, they remained at rest for 1 h before vaccination. The control group remained at rest before vaccination. Immunogenicity was assessed before (Pre) and 1 mo after (Post) the booster using seropositivity rates of total anti-SARS-CoV-2 S1/S2 IgG, geometric mean titers of anti-S1/S2 IgG (GMT), frequency of neutralizing antibodies (NAb) positivity, and NAb activity. At Pre, 16 patients from the exercise group and 16 patients from the control group exhibited seropositivity for IgG (59% vs. 57.1%), and 1 mo after the booster dose, seropositivity occurred in 96% versus 100% of the cases. Only 10 patients from the exercise group and 12 patients from the control group showed positive NAb serology at Pre (37% vs. 42.8%). One month following the booster, NAb positivity was 96% versus 93%. GMT was comparable between groups at Pre. At Post, GMT increased similarly in both groups. Likewise, NAb activity was similar between groups at Pre and increased similarly in both of them as a result of the booster (47.5% vs. 39.9%). In conclusion, a single bout of exercise did not enhance immunogenicity to a homologous booster dose of an inactivated SARS-CoV-2 vaccine among patients with spondyloarthritis. NEW & NOTEWORTHY We tested the role of exercise as an adjuvant to a booster of a COVID-19 vaccine. Immunocompromised patients were immunized after an acute bout of exercise or not. Patients exhibited an excellent immunogenicity in response to
引用
收藏
页码:682 / 688
页数:7
相关论文
共 50 条
  • [21] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
    Fernandes, Eder Gatti
    Silva Lopez-Lopes, Giselle Ibette
    Silva, Valeria Oliveira
    Yamashiro, Rosemeire
    Rolim Madureira, Karen Cristina
    Gallo, Juliana Failde
    Lindoso, Jose Angelo
    Sato, Helena Keico
    D'Avila Limeira de Araujo, Nubia Virginia
    Bacciotte Ramos Nerger, Maria Ligia
    Macedo Brigido, Luis Fernando
    REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2021, 63
  • [22] Immunogenicity and Protective Efficacy of Psoralen-Inactivated SARS-CoV-2 Vaccine in Nonhuman Primates
    Sanders, John W.
    Ewing, Daniel
    Sundaram, Appavu K.
    Gamble, Christopher Scott
    Blevins, Maria
    Liang, Zhaodong
    Sanders, Leigh Ann
    Ornelles, David A.
    Sun, Peifang
    Lenart, Klara
    Feuerstein, Hendrik
    Lore, Karin
    Petrovsky, Nikolai
    Williams, Maya
    Porter, Kevin R.
    VACCINES, 2024, 12 (05)
  • [23] Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
    Jara, Alejandro
    Undurraga, Eduardo A.
    Gonzalez, Cecilia
    Paredes, Fabio
    Fontecilla, Tomas
    Jara, Gonzalo
    Pizarro, Alejandra
    Acevedo, Johanna
    Leo, Katherine
    Leon, Francisco
    Sans, Carlos
    Leighton, Paulina
    Suarez, Pamela
    Garcia-Escorza, Heriberto
    Araos, Rafael
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (10): : 875 - 884
  • [24] Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study
    Ladeira, Filipa
    Nobrega, Claudia
    Cerqueira, Joao
    COVACiMS Collaborators, Carlos
    JOURNAL OF NEUROLOGY, 2025, 272 (04)
  • [25] Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster
    Chantasrisawad, Napaporn
    Puthanakit, Thanyawee
    Kornsitthikul, Katesiree
    Jaru-Ampornpan, Peera
    Tawan, Monta
    Matapituk, Pariya
    Sophonphan, Jiratchaya
    Anugulruengkitt, Suvaporn
    Tangsathapornpong, Auchara
    Katanyutanon, Apirat
    KIDSBOOST study team, K. I. D. S. B. O. O. S. T. study team
    VACCINE: X, 2022, 12
  • [26] Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
    Intapiboon, Porntip
    Seepathomnarong, Purilap
    Ongarj, Jomkwan
    Surasombatpattana, Smonrapat
    Uppanisakorn, Supattra
    Mahasirimongkol, Surakameth
    Sawaengdee, Waritta
    Phumiamorn, Supaporn
    Sapsutthipas, Sompong
    Sangsupawanich, Pasuree
    Chusri, Sarunyou
    Pinpathomrat, Nawamin
    VACCINES, 2021, 9 (12)
  • [27] Long-term immunogenicity in previously vaccinated healthcare workers with inactivated virus vaccine after SARS-CoV-2 infection or booster vaccination
    Terbsiri, Varalee
    Putcharoen, Opass
    Suwanpimolkul, Gompol
    Jantarabenjakul, Watsamon
    Wacharapluesadee, Supaporn
    Champa, Nuntana
    Thippamom, Nattakarn
    Paitoonpong, Leilani
    VACCINE: X, 2023, 14
  • [28] Inactivated SARS-CoV-2 Vaccine Booster Against Omicron Infection Among Quarantined Close Contacts
    Liu, Di
    Feng, Siyang
    Sha, Feng
    Liao, Yuxue
    Xie, Xu
    Huang, Fang
    Kong, Dongfeng
    Zhang, Zhen
    Chen, Zhigao
    Chen, Nixuan
    Gao, Wei
    Feng, Tiejian
    Zhao, Ziyi
    Li, Bingli
    Li, Ying
    Zhu, Fengcai
    Yang, Zhirong
    Lv, Qiuying
    Feng, Zijian
    Tang, Jinling
    JAMA NETWORK OPEN, 2023, 6 (10) : E2339507
  • [29] SARS-CoV-2 Booster Vaccine Response among Patients Receiving Dialysis
    Garcia, Pablo
    Han, Jialin
    Montez-Rath, Maria E.
    Sun, Sumi
    Shang, Tiffany
    Parsonnet, Julie
    Chertow, Glenn M.
    Anand, Shuchi
    Schiller, Brigitte
    Abra, Graham
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (07): : 1036 - 1038
  • [30] Physical Activity: A Strategy to Improve Antibody Response to a SARS-CoV-2 Vaccine Booster Dose in Patients With Autoimmune Rheumatic Diseases
    Gualano, Bruno
    Sieczkowska, Sofia M.
    Lemes, Italo Ribeiro
    da Silva, Rafael Pires
    Pinto, Ana J.
    Mazzolani, Bruna C.
    Smaira, Fabiana I.
    Aikawa, Nadia E.
    Kupa, Leonard V. K.
    Pasoto, Sandra G.
    Medeiros-Ribeiro, Ana C.
    Saad, Carla G. S.
    Yuk, Emily F. N.
    Silva, Clovis A.
    Swinton, Paul
    Hallal, Pedro C.
    Roschel, Hamilton
    Bonfa, Eloisa
    JOURNAL OF PHYSICAL ACTIVITY & HEALTH, 2023, 20 (04): : 311 - 316